Chemical Namefremanezumab-vfrm
Dosage FormInjection (subcutaneously; 225 mg)
Drug ClassMonoclonal antibodies
CompanyTeva Pharmaceuticals USA, Inc.
Approval Year2018


  • To prevent migraines in adults.
Last updated on 11/9/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Ajovy (Fremanezumab-vfrm) Prescribing Information 2018Teva Pharmaceuticals USA, North Wales, PA
Document TitleYearSource
Fremanezumab for preventing migraine. 2020NICE